# A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic Malignancies

> **NCT03082209** · PHASE1 · COMPLETED · sponsor: **AbbVie** · enrollment: 153 (actual)

## Conditions studied

- Advanced Solid Tumors
- Cancer
- Hematologic Malignancies

## Interventions

- **DRUG:** ABBV-621
- **DRUG:** Venetoclax
- **DRUG:** Bevacizumab
- **DRUG:** FOLFIRI

## Key facts

- **NCT ID:** NCT03082209
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-20
- **Primary completion:** 2022-01-21
- **Final completion:** 2022-01-21
- **Target enrollment:** 153 (ACTUAL)
- **Last updated:** 2022-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03082209

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03082209, "A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic Malignancies". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03082209. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*